Systemic therapy in recurrent ovarian cancer: Current treatment options and new drugs

Expert Review of Anticancer Therapy

Volumn 10, Issue 1, 2010, Pages 81-88

  Harter, Philipp ^a   Hilpert, Felix ^b   Mahner, Sven ^c   Heitz, Florian ^a   Pfisterer, Jacobus ^d   Bois, Andreas Du ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Bethanien Hospital Solingen   (Germany)

Author keywords

CA 125; Chemotherapy; Platinum resistant; Platinum sensitive; Recurrent ovarian cancer; Targeted therapy

Indexed keywords

ABAGOMOVAB; BEVACIZUMAB; BIBF 1120; CA 125 ANTIGEN; CANFOSFAMIDE; CARBOPLATIN; CATUMAXOMAB; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; LEUPRORELIN; LONAFARNIB; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; OREGOVOMAB; PACLITAXEL; PAZOPANIB; TAMOXIFEN; TOPOTECAN; TRABECTEDIN; TREOSULFAN; UNCLASSIFIED DRUG; VANDETANIB;

ALOPECIA; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG HYPERSENSITIVITY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HORMONAL THERAPY; HUMAN; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SYSTEMIC THERAPY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 74749089537     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.165     Document Type: Review

References (44)

1. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized Phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 15, 1234-1244 (2009).
2. Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 6th Annual Report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet. 95(Suppl. 1), 161-192 ( 2006).
3. Du Bois A, Lück HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst. 95, 1320-1329 (2003).
4. Du Bois A, Weber B, Rochon J et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux Pour l'Etude des Cancers Ovariens. J. Clin. Oncol. 24, 1127-1135 (2006).
5. Pfisterer J, Weber B, Reuss A et al. Randomized Phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl Cancer Inst. 98, 1036-1045 (2006).
6. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9(3), 389-393 (1991).
7. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36(2), 207-211 (1990).
8. Rustin GJ, van der Burg ME; on behalf of MRC and EORTC Collaborators. Early treatment of relapsed ovarian cancer based on CA125 level alone versus delayed treatment based on conventional clinical indicators: results of the randomized MRC OV05 and EORTC 55955 trials. J. Clin. Oncol. 27(18S), (2009) (Abstract 1).
9. Du Bois A, Meier W, Lueck HJ et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomized trial of the german Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann. Oncol. 13, 251-257 (2002).
10. Kristensen G, Kaern J, Baekelandt M et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: a NSGO study. J. Clin. Oncol. 26S, (2008) (Abstract 5508).
11. Meier W, du Bois A, Reuss A et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized Phase III trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group (AGO-OVAR). Gynecol. Oncol. 114, 199-205 (2009).
12. Ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15(6), 2183-2193 (1997).
13. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a gynecologic oncology group study. Gynecol. Oncol. 101(3), 436-440 (2006).
14. Sehouli J, Stengel D, Oskay-Oezcelik G et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a Phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol. 26, 3176-3182 (2008).
15. Sehouli J, Oskay-Oezcelik G, Stengel D et al. Topotecan weekly versus routine 5-day schedule in patients with platinum resistant ovarian cancer (tower): a randomized, mutlicenter trial of the North-Eastern German Society of Gynaecological Oncology (NOGGO). J. Clin. Oncol. 27(18S), (2009) (Abstract 5553).
16. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312-3322 (2001).
17. Mutch DG, Orlando M, Goss T et al. Randomized Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. (25), 2811-2818 (2007).
18. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol. 26, 890-896 (2008).
19. Vergote I, Finkler N, del Campo J et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur. J. Cancer 45, 2324-2332 (2009).
20. Parmar M, Lederman JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR- 2.2 trial. Lancet 361, 2099-2106 (2003).
21. Gonzalez-Martin AJ, Calvo E, Bover I et al. Randomized Phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann. Oncol. 16(5), 749-755 (2005).
22. Du Bois A, Luck HJ, Pfisterer J et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) ovarian cancer study group. Ann. Oncol. 12(8), 1115-1120 (2001).
23. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24(29), 4699-4707 (2006).
24. Du Bois A, Pfisterer J, Burchardi N et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective Phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-UT). Gynecol. Oncol. 107(3), 518-525 (2007).
25. Ferrero JM, Weber B, Geay JF et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO Phase II trial. Ann. Oncol. 18(2), 263-268 (2007).
26. Alberts DS, Liu PY, Wilczynski SP et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol. Oncol. 108(1), 90-94 (2008).
27. Pujade-Lauraine E, Mahner S, Kaern J. et al. A randomized, Phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer: CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J. Clin. Oncol. 27, 18s, (2009) (LBA5509).
28. Monk BJ, Herzog T, Kaye S et al. A randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer. Ann. Oncol. 19(S8), (2008) (Abstract LBA4).
29. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25, 5165-5171 (2007).
30. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
31. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26(12), 2013-2019 (2008).
32. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25, 5180-5186 (2007).
33. Mok TS, Wu Yl, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pul monary adenocarcinoma. N. Engl. J. Med. (2009).
34. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
35. Ledermann JA, Rustin GJ, Hackshaw A et al. A randomized Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer. J. Clin. Oncol. 27, 15S, (2009) (Abstract 5501).
36. Harter P, Huober J, Pfisterer J et al. A Phase I dose escalation and pharmacokinetic study of BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced gynecological malignancies. J. Clin. Oncol. 25, 18S (2007) (Abstract 3561).
37. Friedlander M, Hancock KC, Benigno B et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube, and peritoneal cancers: final results of a Phase II study. Presented at the 33rd European Society for Medical Oncology (ESMO) Congress. Stockholm, Sweden, 12-16 September, 2008 (Abstract 6630).
38. Wagner U, Du Bois A, Pfisterer J et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - a Phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol. Oncol. 105(1), 132-137 (2007).
39. Berek J, Taylor P, Mcguire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J. Clin. Oncol. 27(3), 418-425 (2009).
40. Pfisterer J, Du Bois A, Sehouli J et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A Phase I trial of the AGO-OVAR. Ann. Oncol. 17(10), 1568-1577 (2006).
41. Parsons SL, Kutarska E, Koralewski P et al. Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: results of a Phase II/III study. J. Clin. Oncol. 25(18S), (2007) (Abstract 5520).
42. Farmer H, Mccabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005).
43. Audeh MW, Penson RT, Friedlander M et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J. Clin. Oncol. 27, 15S, (2009) (Abstract 5500).
44. Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, Du Bois A. The role of cytoreductive surgery in recurrent ovarian cancer. Expert Rev. Anticancer Ther 9(7), 917-922 (2009).